Pharmacological Approaches To Repair the Injured Spinal Cord
- 1 April 2006
- journal article
- review article
- Published by Mary Ann Liebert Inc in Journal of Neurotrauma
- Vol. 23 (3-4), 318-334
- https://doi.org/10.1089/neu.2006.23.318
Abstract
Acute traumatic spinal cord injury (SCI) results in a devastating loss of neurological function below the level of injury and adversely affects multiple systems within the body. The pathobiology of SCI involves a primary mechanical insult to the spinal cord and activation of a delayed secondary cascade of events, which ultimately causes progressive degeneration of the spinal cord. Whereas cell death from the mechanical injury is predominated by necrosis, secondary injury events trigger a continuum of necrotic and apoptotic cell death mechanisms. These secondary events include vascular abnormalities, ischemia-reperfusion, glutamate excitotoxicity and disturbances in ionic homeostasis, oxidative cell injury, and a robust inflammatory response. No gold standard therapy for SCI has been established, although clinical trials with methylprednisolone (NASCIS II and III) and GM-1 ganglioside (Maryland and Sygen) have demonstrated modest, albeit potentially important therapeutic benefits. In light of the overwhelming impact of SCI on the individual, other therapeutic interventions are urgently needed. A number of promising pharmacological therapies are currently under investigation for neuroprotective abilities in animal models of SCI. These include the sodium (Na+) channel blocker riluzole, the tetracycline derivative minocycline, the fusogen copolymer polyethylene glycol (PEG), and the tissue-protective hormone erythropoietin (EPO). Moreover, clinical trials investigating the putative neuroprotective and neuroregenerative properties ascribed to the Rho pathway antagonist, Cethrin® (BioAxone Therapeutic, Inc.), and implantation of activated autologous macrophages (ProCord®; Proneuron Biotechnologies) in patients with thoracic and cervical SCI are now underway. We anticipate that these studies will harken an era of renewed interest in translational clinical trials. Ultimately, due to the multi-factorial pathophysiology of traumatic SCI, effective therapies will require combined approaches.Keywords
This publication has 72 references indexed in Scilit:
- Passive or Active Immunization with Myelin Basic Protein Impairs Neurological Function and Exacerbates Neuropathology after Spinal Cord Injury in RatsJournal of Neuroscience, 2004
- Therapeutic Strategies Targeting Caspase Inhibition Following Spinal Cord Injury in RatsExperimental Neurology, 2002
- The Role of Steroids in Acute Spinal Cord InjurySpine, 2001
- Neuroprotection mediated by changes in the endothelial actin cytoskeletonJCI Insight, 2000
- Lipid peroxidation inhibition in spinal cord injuryNeuroReport, 2000
- Involvement of Activated Caspase‐3‐Like Proteases in N‐Methyl‐D‐Aspartate‐Induced Apoptosis in Cerebrocortical NeuronsJournal of Neurochemistry, 2000
- The relationships among the severity of spinal cord injury, residual neurological function, axon counts, and counts of retrogradely labeled neurons after experimental spinal cord injuryExperimental Neurology, 1995
- Lipid antioxidants in acute central nervous system injuryAnnals of Emergency Medicine, 1993
- A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord InjuryThe New England Journal of Medicine, 1990
- The effect of nimodipine and dextran on axonal function and blood flow following experimental spinal cord injuryJournal of Neurosurgery, 1989